Zerres K, Rudnik-Schöneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I
Institute for Human Genetics, University of Bonn, Germany.
J Neurol Sci. 1997 Feb 27;146(1):67-72. doi: 10.1016/s0022-510x(96)00284-5.
We analyzed clinical data of 569 patients in two combined series with childhood and juvenile proximal SMA. This cohort included only patients who had achieved the ability to sit unaided (type II and III SMA). The survival rate among 240 type II patients (who sat but never walked) was 98.5% at 5 years and 68.5% at 25 years. SMA III (n = 329) (those who walked and had symptoms before age 30 years) was subdivided into those with an onset before and after age 3 years (type IIIa, n = 195; SMA IIIb, n = 134). In patients with SMA III, life expectancy is not significantly less than a normal population. The probabilities of being able to walk at 10 years after onset was 70.3%, and at 40 years, 22.0% in SMA IIa. For SMA IIIb, 96.7% were walking 10 years after onset and 58.7% at 40 years. The subdivision of type III SMA was justified by the probability of being ambulatory depending on age at onset; the prognosis differed for those with onset before or after age 3 years. The data provide a reliable basis of the natural history of proximal SMA and support a classification system that is based primarily on age at onset and the achievement of motor milestones.
我们分析了两个合并队列中569例儿童及青少年近端型脊髓性肌萎缩症患者的临床数据。该队列仅纳入了能够独立坐立的患者(II型和III型脊髓性肌萎缩症)。240例II型患者(能坐但从未行走)的5年生存率为98.5%,25年生存率为68.5%。III型脊髓性肌萎缩症(n = 329)(30岁前行走且有症状者)又细分为3岁前起病和3岁后起病两组(IIIa型,n = 195;IIIb型,n = 134)。对于III型脊髓性肌萎缩症患者,其预期寿命与正常人群相比并无显著差异。IIa型患者起病后10年能够行走的概率为70.3%,40年时为22.0%。对于IIIb型患者,起病后10年能够行走的比例为96.7%,40年时为58.7%。III型脊髓性肌萎缩症的细分是合理的,因为其行走能力的概率取决于起病年龄;3岁前或3岁后起病的患者预后不同。这些数据为近端型脊髓性肌萎缩症的自然病史提供了可靠依据,并支持了一个主要基于起病年龄和运动里程碑达成情况的分类系统。